Global Information
회사소개 | 문의 | 위시리스트

역류성 식도염(위식도 역류질환) : 파이프라인 리뷰

Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline Review, H1 2019

리서치사 Global Markets Direct
발행일 2019년 02월 상품 코드 232845
페이지 정보 영문 87 Pages
가격
US $ 2,000 ₩ 2,308,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,616,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,924,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


역류성 식도염(위식도 역류질환) : 파이프라인 리뷰 Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline Review, H1 2019
발행일 : 2019년 02월 페이지 정보 : 영문 87 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

위액이 식도로 역류하는 상태를 위식도 역류질환(GERD)이라고 부르며, 오심, 가슴 쓰림, 구토 등의 증상이 나타납니다. 식도 하부 괄약근(LES)의 잘못된 개폐를 일으키는 과식, 비만, 임신, 지방이 많은 음식, 일부 의약품 등이 질병소인입니다.

세계의 역류성 식도염(위식도 역류질환)(Reflux Esophagitis (Gastroesophageal Reflux Disease)) 치료제 파이프라인에 대해 조사했으며, 현재의 개발 파이프라인 상황과 최신 동향, 치료제 개요, 주요 기업 및 개발중인 제품 리뷰 등의 정보를 전해드립니다.

목차

서론

  • 분석 범위

역류성 식도염(위식도 역류질환) 개요

치료제 개발

  • 역류성 식도염(위식도 역류질환)용 파이프라인 제품 : 개요
  • 역류성 식도염(위식도 역류질환)용 파이프라인 제품 : 비교 분석

역류성 식도염(위식도 역류질환) : 개발중인 치료제 - 기업별

역류성 식도염(위식도 역류질환) : 개발중인 치료제 - 대학 및 연구기관별

역류성 식도염(위식도 역류질환) : 파이프라인 제품 개요

  • 후기 단계 제품
  • 임상 단계 제품
  • 초기 단계 제품

역류성 식도염(위식도 역류질환) : 개발중인 제품 - 기업별

역류성 식도염(위식도 역류질환) : 개발중인 제품 - 대학 및 연구기관별

역류성 식도염(위식도 역류질환) : 치료제 개발에 참여하고 있는 기업

  • Ahn-Gook Pharmaceutical Co., Ltd.
  • aRigen Pharmaceuticals, Inc.
  • Cempra, Inc.
  • Daewoong Pharmaceutical Co., Ltd.
  • Eisai Inc.
  • Ironwood Pharmaceuticals, Inc.
  • Johnson & Johnson
  • RaQualia Pharma Inc.
  • Shire Plc
  • Sucampo Pharmaceuticals, Inc.
  • Vecta Ltd.
  • Wockhardt Limited
  • Yuhan Corporation
  • Yuyu Pharma, Inc.

역류성 식도염(위식도 역류질환) : 치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 병용 제품(Combination Products)별
  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

치료제 개요

  • ARH-1029
  • cobiprostone
  • DWJ-1367
  • E-3710
  • esomeprazole magnesium
  • G-17DT
  • IW-3718
  • JNJ-26070109
  • omeprazole
  • pantoprazole
  • RQ-00000004
  • RQ-00000774
  • Small Molecule for Peptic Ulcers
  • Small Molecules to Agonize Motilin Receptor for GERD and Diabetic Gastroparesis
  • Small Molecules to Block Proton Pump for Gastrointestinal Disorders
  • SSP-002358
  • tenatoprazole
  • YH-4808
  • YY-DXR
    • 제품 개요
    • 작용기서
    • R&D 진전

최신 파이프라인 동향

휴지중인 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

  • 주목 뉴스 및 프레스 릴리스

부록

도표

KSM 15.10.14

List of Tables

  • Number of Products under Development for Reflux Esophagitis (Gastro esophageal Reflux Disease), H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Ahn-Gook Pharmaceutical Co Ltd, H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by CJ HealthCare Corp, H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Eisai Co Ltd, H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Handa Pharmaceuticals LLC, H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Ilyang Pharmaceutical Co Ltd, H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Ironwood Pharmaceuticals Inc, H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by RaQualia Pharma Inc, H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Sam-A Pharm Co Ltd, H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Yooyoung Pharm Co Ltd, H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Yuyu Pharma Inc, H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Dormant Projects, H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Dormant Projects, H1 2019 (Contd..1), H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Discontinued Products, H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Discontinued Products, H1 2019 (Contd..1), H1 2019

List of Figures

  • Number of Products under Development for Reflux Esophagitis (Gastro esophageal Reflux Disease), H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products by Targets, H1 2019
  • Number of Products by Stage and Targets, H1 2019
  • Number of Products by Mechanism of Actions, H1 2019
  • Number of Products by Stage and Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Molecule Types, H1 2019

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Reflux Esophagitis - Pipeline Review, H1 2019, provides an overview of the Reflux Esophagitis (Gastrointestinal) pipeline landscape.

When the liquid content of the stomach refluxes into the oesophagus, that condition is called Gastro esophageal reflux disease (GERD). It is a chronic condition. The symptoms of GERD are nausea, heartburn and vomiting. The predisposing factors include eating large meals, which can cause the Lower Esophageal Sphincter (LES) to open inappropriately, as well as obesity, pregnancy, greasy food and certain drugs.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Reflux Esophagitis - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Reflux Esophagitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Reflux Esophagitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Reflux Esophagitis (Gastro esophageal Reflux Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 6, 6, 4, 1 and 1 respectively.

Reflux Esophagitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Reflux Esophagitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Reflux Esophagitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Reflux Esophagitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Reflux Esophagitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Reflux Esophagitis (Gastrointestinal)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Reflux Esophagitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Reflux Esophagitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Overview
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Companies Involved in Therapeutics Development
    • Ahn-Gook Pharmaceutical Co Ltd
    • Chong Kun Dang Pharmaceutical Corp
    • CJ HealthCare Corp
    • Daewoong Pharmaceutical Co Ltd
    • Eisai Co Ltd
    • Handa Pharmaceuticals LLC
    • Ilyang Pharmaceutical Co Ltd
    • Ironwood Pharmaceuticals Inc
    • Jeil Pharmaceutical Co Ltd
    • RaQualia Pharma Inc
    • Sam-A Pharm Co Ltd
    • Sun Pharma Advanced Research Company Ltd
    • Takeda Pharmaceutical Co Ltd
    • Yooyoung Pharm Co Ltd
    • Yuyu Pharma Inc
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Drug Profiles
    • (esomeprazole + sodium bicarbonate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • azeloprazole sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ceclazepide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CG-20043 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CJ-30065 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • colesevelam - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dexlansoprazole DR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DWP-14012 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • esomeprazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • G-17DT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HND-009 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ilaprazole DR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IYHCR-17 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JP-1366 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • naronapride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • netazepide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pantoprazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pantoprazole DR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RQ-00000774 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SA-15001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tegoprazan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vonoprazan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • X-842 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YY-DXR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Dormant Projects
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Discontinued Products
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Product Development Milestones
    • Featured News & Press Releases
      • Oct 08, 2018: Ironwood Pharmaceuticals presents IW-3718 data at the American College of Gastroenterology 2018 Annual Scientific Meeting
      • Jul 06, 2018: Ministry approves CJ Healthcares Gastro esophageal reflux treatment
      • Jul 06, 2018: RaQualia Announces Receipt of Milestone Payment from CJ HealthCare
      • Jun 21, 2018: Ironwood begins two Phase III trials of IW-3718
      • Jun 05, 2018: Ironwood Pharmaceuticals Presents IW-3718 Data Showing Improvements in Heartburn and Regurgitation Symptoms in Patients with Persistent GERD at Digestive Disease Week 2018
      • Jun 05, 2018: Ironwood Pharmaceuticals Presents IW-3718 Data Showing Improvements in Heartburn and Regurgitation Symptoms in Patients with Persistent GERD at Digestive Disease Week 2018
      • May 23, 2018: Ironwood Pharmaceuticals to Highlight Clinical Data for IW-3718 in Persistent Gastro esophageal Reflux Disease (GERD) at Digestive Disease Week 2018
      • Apr 16, 2018: First clinical study successfully completed with X842, an innovative promising treatment for severe erosive GERD
      • Jul 20, 2017: Ironwood Pharmaceuticals Reports Positive Top-line Results from IW-3718 Phase IIb Trial in Uncontrolled Gastro esophageal Reflux Disease
      • Mar 09, 2017: Ironwood Pharmaceuticals provides update on key pipeline program IW-3718 at R&D Day 2017
      • Nov 16, 2016: Renexxion Achieves Positive FDA Guidance for Phase 3-ready GI Drug Naronapride
      • Jul 11, 2016: Takeda Announces FDA Approval of Dexilant (dexlansoprazole) for Patients 12-17 Years of Age
      • Mar 23, 2016: Ironwood Pharmaceuticals Initiates Phase IIb Clinical Trial of IW-3718 in Refractory Gastro esophageal Reflux Disease
      • Feb 18, 2016: RaQualia Receives a Patent Allowance for Acid Pump Antagonist in Korea
      • Jan 27, 2016: FDA Approves Takeda's Dexilant SoluTab (dexlansoprazole)
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q
 
BCC Research